
ALPN
Healthcare · Biotechnology · $4.46B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · -13.5% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 9, 2024 | After the close | -0.41 | -0.28 | +31.7% |
| Mar 18, 2024 | After the close | -0.34 | 0.12 | +135.3% |
| Nov 14, 2023 | After the close | -0.33 | -0.24 | +27.3% |
| Aug 14, 2023 | After the close | -0.37 | -0.27 | +27.0% |
| May 11, 2023 | After the close | -0.37 | -0.28 | +24.3% |
| Mar 23, 2023 | After the close | -0.27 | -0.41 | -51.9% |
| Nov 14, 2022 | After the close | -0.10 | -0.42 | -320.0% |
| Aug 11, 2022 | After the close | -0.39 | -0.60 | -53.8% |
| May 12, 2022 | After the close | -0.19 | -0.25 | -31.6% |
| Mar 17, 2022 | After the close | -0.30 | -0.52 | -73.3% |
| Nov 10, 2021 | After the close | 0.01 | -0.55 | -5600.0% |
| Aug 10, 2021 | After the close | -0.40 | -0.46 | -15.0% |
| May 13, 2021 | After the close | -0.36 |
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and…
| -0.45 |
| -25.0% |
| Mar 18, 2021 | After the close | -0.31 | -0.27 | +12.9% |
| Nov 12, 2020 | After the close | -0.23 | -0.28 | -21.7% |
| Aug 11, 2020 | After the close | 0.54 | -0.53 | -198.1% |
| May 14, 2020 | After the close | -0.47 | -0.30 | +36.2% |
| Mar 30, 2020 | After the close | -0.58 | -0.33 | +43.1% |
| Nov 13, 2019 | After the close | -0.68 | -0.62 | +8.8% |
| Aug 13, 2019 | After the close | -0.68 | -0.64 | +5.9% |
| May 9, 2019 | After the close | -0.69 | -0.70 | -1.4% |
| Mar 18, 2019 | After the close | -0.80 | -0.80 | 0.0% |
| Nov 8, 2018 | After the close | -0.57 | -0.88 | -54.4% |
| Aug 9, 2018 | After the close | -0.43 | -0.48 | -11.6% |
| May 14, 2018 | After the close | -0.39 | -0.38 | +2.6% |
| Mar 28, 2018 | After the close | -0.36 | -0.33 | +8.3% |